E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/31/2006 in the Prospect News Biotech Daily.

Shire at sector perform by RBC

RBC Capital Markets analyst Douglas Miehm rated Shire plc at sector perform, above average risk, on news of the company's financial results. The company reported earnings per share of $0.44, ahead of RBC's estimate of $0.40 and the consensus forecast of $0.37. Shire had revenue of $439.1 million in the second quarter, up 3% versus last year and in line with both the analyst's estimate of $438.5 million and the consensus forecast of $440.1 million. RBC raised its price target to $49 from $47. Shares of the Basingstoke, England-based pharmaceutical company were up $1.53, or 3.26%, at $48.51 on volume of 877,382 shares versus the three-month running average of 522,912 shares. (Nasdaq: SHPGY)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.